Intervention and Demographics:

1. Out of 101 patients, 80 (79.21%) underwent TAVI, with an average age of 81.2 years—significantly lower than the average age (83.8 years) of the non‑TAVI group.
2. Although gender was not significantly associated with the decision to perform TAVI, a negative association was observed with age, indicating that younger patients were more likely to be treated with TAVI.

Prosthesis Selection and CT Findings:

1. Pre‑TAVI CT measurements enabled precise determination of the native valve dimensions, facilitating optimal prosthesis sizing.
2. The strong correlation between CT‑measured diameters and the implanted prosthesis size (p = 5.48×10⁻¹âµ) underscores the critical role of CT in procedural planning.
3. The most frequently implanted prosthesis sizes were 26 mm (37.5%), followed by 23 mm (25%) and 29 mm (17.5%).
4. Edwards Sapien was the most commonly used model (62.5%), with CoreValve Evolut accounting for 18.8% of the cases.

Complications and Mortality:

1. During hospitalization, 46.25% of patients experienced at least one complication.
2. The most common complications were conduction abnormalities (35%), which in some cases necessitated pacemaker implantation, and paravalvular leaks (29%). Other complications included vascular access injuries, prosthesis placement failures, strokes, and coronary obstructions.
3. The overall mortality during follow‑up was 17.5%, with 35.7% of these deaths directly attributable to TAVI‑related complications. Additional analyses indicated that male gender (p = 0.0189) and prosthesis placement failure (p = 0.0297) were significantly associated with increased mortality risk.